Starpharma (ASX:SPL) share price rebounds after receiving Indian approval for COVID-19 product

This Aussie healthcare company is aiming to help with the COVID-19 crisis in India…

| More on:
asx share associated with COVID vaccine represented by lab tech drawing down syringe

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price has bounced back from weakness this morning and is pushing higher late on Friday.

In afternoon trade, the biotechnology company's shares are up 1% to $1.69.

This latest gain means the Starpharma share price is now up 60% since this time last year.

Why is the Starpharma share price pushing higher?

Investors have been buying Starpharma's shares on Friday after it confirmed that its COVID-fighting Viraleze antiviral nasal spray has been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO).

The CDSCO is part of the Indian Ministry of Health and Family Welfare.

According to the release, consumers in India can now purchase the Viraleze product via is website. It is also busy finalising local distribution arrangements with potential commercial partners into both the private (consumer) and Government markets.

In light of this, Starpharma is progressing product supply preparations for the Indian market.

Huge market opportunity

The company notes that India has a population of more than 1.3 billion and the ongoing COVID-19 crisis in the country has seen the death toll surpass 359,000 people, and more than 29 million cases.

The release explains that at the peak of the crisis, there were more than 400,000 cases being reported per day, the highest of any country since the pandemic began.

In light of this, management sees a huge opportunity for Viraleze in the Indian market. This is because it is an easy-to-use antiviral nasal spray, which can be stored at room temperature and does not require cold storage or specialised transportation.

It contains SPL7013 (astodrimer sodium), which has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2 (the virus that causes COVID-19).

SPL7013 has also been shown to be virucidal, rapidly inactivating >99.9% of SARS-CoV-2 within 60 seconds with potent antiviral activity shown in multiple strains and variants of the virus. This is a big positive given the various strains that have been developing, particularly in India.

Starpharma's CEO, Dr Jackie Fairley, commented: "India continues to record hundreds of thousands of COVID-19 cases every day. Starpharma has worked extremely hard to achieve expedited registration of Viraleze in India given the significant need, and we are pleased that Indian consumers are able to access the product immediately through our webstore www.viraleze.co. We are also well advanced in progressing negotiations for distribution arrangements with potential local commercial partners to enable greater access to the product."

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »